Ezobresib is an investigational new drug that has been evaluated for the treatment of cancer. It inhibits Bromodomain and Extra-Terminal domain (BET) proteins, with potential antineoplastic activity.[1] Developed by Bristol Myers Squibb, this therapeutic agent has been studied for its efficacy in treating various cancers, including solid tumors and hematological malignancies.[2] Despite showing promise in early-phase clinical trials, recent developments suggest that Bristol Myers Squibb has decided to discontinue further development of ezobresib.[3]

References

  1. ^ Ma Z, Zhang C, Bolinger AA, Zhou J (October 2024). "An updated patent review of BRD4 degraders". Expert Opinion on Therapeutic Patents. 34 (10): 929–951. doi:10.1080/13543776.2024.2400166. PMC 11427152. PMID 39219068.
  2. ^ "Clinical Trials Using Ezobresib". National Cancer Institute.
  3. ^ Brown A. "Bristol backs out of BET inhibition". ApexOnco.


Allikas: https://en.wikipedia.org/wiki/Ezobresib
No tags for this post.